These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34510702)

  • 1. Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
    Correale M; Mazzeo P; Magnesa M; Fortunato M; Tricarico L; Leopizzi A; Mallardi A; Mennella R; Tucci S; Brunetti ND
    Clin Physiol Funct Imaging; 2021 Nov; 41(6):505-513. PubMed ID: 34510702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Yang Y; Shen C; Lu J; Fu G; Xiong C
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):177-182. PubMed ID: 34711748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
    Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.
    Correale M; Mallardi A; Mazzeo P; Tricarico L; Diella C; Romano V; Ferraretti A; Leopizzi A; Merolla G; Di Biase M; Brunetti ND
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100486. PubMed ID: 32140553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
    Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of β-blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation.
    Galves R; Da Costa A; Pierrard R; Bayard G; Guichard JB; Isaaz K
    Echocardiography; 2020 Sep; 37(9):1392-1398. PubMed ID: 32815195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
    Mazzetti S; Scifo C; Abete R; Margonato D; Chioffi M; Rossi J; Pisani M; Passafaro G; Grillo M; Poggio D; Mortara A
    ESC Heart Fail; 2020 Jun; 7(3):964-972. PubMed ID: 32233080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Pericas P; Mas-Lladó C; Ramis-Barceló MF; Valadrón I; Noris Mora M; Pasamar Márquez L; González Colino R; Forteza Albertí JF; Peral Disdier V; Rossello X
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):167-175. PubMed ID: 33599965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different right ventricular dysfunction and pulmonary coupling in acute heart failure according to the left ventricular ejection fraction.
    Palazzuoli A; Cartocci A; Pirrotta F; Vannuccini F; Campora A; Martini L; Dini FL; Carluccio E; Ruocco G
    Prog Cardiovasc Dis; 2023; 81():89-97. PubMed ID: 37536484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Öz TK; Abdelnabi M; Fiore C; Almaghraby A; Cihan D; Babazade N; Haseeb Raza Naqvi S; Omar B; Dağdeviren B
    Minerva Cardiol Angiol; 2022 Aug; 70(4):431-438. PubMed ID: 34713680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.